Home › NDC Lookup › RxCUI directory › RxCUI 1148797

12 HR tapentadol 100 MG Extended Release Oral Tablet — RxCUI 1148797

RxNorm drug concept · Semantic clinical drug
RxCUI 1148797 Semantic clinical drug · SCD ● Current RxNorm concept 10 FDA products 15 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1148797
Official name12 HR tapentadol 100 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astapentadol 100 MG 12HR Extended Release Oral Tablet
FDA products mapped10
Package NDCs mapped15
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tapentadol: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Tapentadol is a prescription opioid used for severe pain — the kind that other treatments can't adequately manage. The immediate-release tablets are for short-term acute pain, whil...
  • What exactly is tapentadol used for, and is it the same as regular opioids?
  • The most important rule: swallow the extended-release tablet whole with water — never crush, cut, chew, or dissolve it. Breaking it down releases the full dose all at once, which c...
  • How do I take the extended-release tablet correctly?
📖 Read our full Tapentadol guide →

🕸️ Concept Web — How 12 HR tapentadol 100 MG Extended Release Oral Ta... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 12 HR tapentadol 100 MG Extended Release Oral Tablet RxCUI 1148797

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tapentadol 787390
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Nucynta 854137
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tapentadol Extended Release Oral Tablet 1148796
    • Tapentadol Oral Product 1160875
    • Tapentadol Pill 1160876
    • Tapentadol Extended Release Oral Tablet [Nucynta] 1149366
    • Nucynta Oral Product 1178796
    • Nucynta Pill 1178797
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tapentadol 100 MG SCDC · 825407
  • Tapentadol Extended Release Oral Tablet SCDF · 1148796
  • Tapentadol Oral Product SCDG · 1160875
  • Tapentadol Pill SCDG · 1160876

Brand-Name Concepts

📦 FDA Products & Package NDCs

10 products · 15 package NDCs
15 package NDCs map to RxCUI 1148797 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00054-0936-21 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTI... TAPENTADOL Hikma Pharmaceuticals USA Inc. 2025-12-15
00054-0937-21 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTI... TAPENTADOL Hikma Pharmaceuticals USA Inc. 2025-12-15
00054-0938-21 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTI... TAPENTADOL Hikma Pharmaceuticals USA Inc. 2025-12-15
00054-0939-21 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTI... TAPENTADOL Hikma Pharmaceuticals USA Inc. 2025-12-15
00054-0940-21 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTI... TAPENTADOL Hikma Pharmaceuticals USA Inc. 2025-12-15
24510-0058-01 10 BLISTER PACK in 1 CARTON (24510-058-01) / 10 TABLET, FIL... Nucynta ER Collegium Pharmaceutical, Inc. 2019-04-19
24510-0058-60 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (24510-... Nucynta ER Collegium Pharmaceutical, Inc. 2019-04-19
24510-0116-01 10 BLISTER PACK in 1 CARTON (24510-116-01) / 10 TABLET, FIL... Nucynta ER Collegium Pharmaceutical, Inc. 2019-04-19
24510-0116-60 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (24510-... Nucynta ER Collegium Pharmaceutical, Inc. 2019-04-19
24510-0174-01 10 BLISTER PACK in 1 CARTON (24510-174-01) / 10 TABLET, FIL... Nucynta ER Collegium Pharmaceutical, Inc. 2019-04-19
24510-0174-60 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (24510-... Nucynta ER Collegium Pharmaceutical, Inc. 2019-04-19
24510-0232-01 10 BLISTER PACK in 1 CARTON (24510-232-01) / 10 TABLET, FIL... Nucynta ER Collegium Pharmaceutical, Inc. 2019-04-19
24510-0232-60 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (24510-... Nucynta ER Collegium Pharmaceutical, Inc. 2019-04-19
24510-0291-01 10 BLISTER PACK in 1 CARTON (24510-291-01) / 10 TABLET, FIL... Nucynta ER Collegium Pharmaceutical, Inc. 2019-04-19
24510-0291-60 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (24510-... Nucynta ER Collegium Pharmaceutical, Inc. 2019-04-19
Observed labelers: Collegium Pharmaceutical, Inc. (10) · Hikma Pharmaceuticals USA Inc. (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.